Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Evaluating the function of covalent immune recruiter molecules in an in vivo murine model
FY 2020-21
Summary
A promising targeted approach to treat cancer is to use the body's own immune system to attack cancer cells. Antibodies possess a unique ability to redirect immune function against cancer cells and form the basis of a large class of FDA approved tumour immunotherapeutic antibodies. However, these therapeutics have limitations with regards to tissue accessibility, inadequate dosage, and weak interactions with the immune/cancer cells. A possible solution is to use the antibodies already present in the body. Synthetic small molecule therapeutics are a way to reprogram antibodies naturally present within the body to recognize and mark malignant cells for destruction. One such approach is the use of covalent immune recruiters (CIR) as an adapter or bridge between antibodies and the cancer cell. My project looks at a CIR molecule that specifically targets a prostate cancer protein. After binding to pre-existing antibodies in the body, the CIR molecule can then bind to the cancer cells. By binding both the antibody and the cancer cell, the CIR targets the antibodies towards the cancer cell and triggers an immune response to kill the aberrant cells. My project will evaluate the CIR's ability to treat a tumour in a mouse model with a fully intact immune system. Following the cancer cell transplantation into mice, I can treat the tumour using the CIR. I can determine the efficacy of the CIR by examining the extent of cancer cell death, tumour reduction and immune cell recruitment/activation. My project will not only validate the existing CIR molecule as a potential therapeutic for prostate cancer but will also provide a firm foundation for future CIR research since CIRs may be synthesized to target a variety of cancer cells.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449494
Name
Raajkumar Akshaya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the function of covalent immune recruiter molecules in an in vivo murine model
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Therapy; Cancer Treatment; Chemical Biology; Immune Cells; Immunology; In Vivo Study; Murine Model; Natural Killer Cells; Prostate Cancer; Translational Research
Abstract
A promising targeted approach to treat cancer is to use the body's own immune system to attack cancer cells. Antibodies possess a unique ability to redirect immune function against cancer cells and form the basis of a large class of FDA approved tumour immunotherapeutic antibodies. However, these therapeutics have limitations with regards to tissue accessibility, inadequate dosage, and weak interactions with the immune/cancer cells. A possible solution is to use the antibodies already present in the body. Synthetic small molecule therapeutics are a way to reprogram antibodies naturally present within the body to recognize and mark malignant cells for destruction. One such approach is the use of covalent immune recruiters (CIR) as an adapter or bridge between antibodies and the cancer cell. My project looks at a CIR molecule that specifically targets a prostate cancer protein. After binding to pre-existing antibodies in the body, the CIR molecule can then bind to the cancer cells. By binding both the antibody and the cancer cell, the CIR targets the antibodies towards the cancer cell and triggers an immune response to kill the aberrant cells. My project will evaluate the CIR's ability to treat a tumour in a mouse model with a fully intact immune system. Following the cancer cell transplantation into mice, I can treat the tumour using the CIR. I can determine the efficacy of the CIR by examining the extent of cancer cell death, tumour reduction and immune cell recruitment/activation. My project will not only validate the existing CIR molecule as a potential therapeutic for prostate cancer but will also provide a firm foundation for future CIR research since CIRs may be synthesized to target a variety of cancer cells.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Raajkumar, Akshaya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~